Inverness buys ischemia test
This article was originally published in The Gray Sheet
Executive Summary
In vitro diagnostic blood test for use with troponin protein tests and electrocardiograms to help rule out heart attacks is acquired by Inverness under a $22.4 mil., all-stock deal to purchase developer Ischemia Technologies. The Ischemia Modified Albumin test was cleared via 510(k) in February 2003. The $30 test addresses a market of roughly 6 mil. patients in the U.S. who present with chest pains at emergency rooms each year. Privately held ITI had 2004 revenue of $1 mil. (1"The Gray Sheet" Feb. 24, 2003, p. 17)...
You may also be interested in...
ITI Test To Help Rule Out Heart Attacks Has $180 Mil. U.S. Market Potential
Ischemia Technologies, Inc. (ITI) plans to sell its Albumin Cobalt Binding (ACB) test for $30 when it begins a controlled market release in March
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.